Skip to content

Study · Non-randomized trial · 2026

1 result

Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.

Cronenberger C, Amin NB, Le VH, Carvajal-Gonzalez S, Ashworth AL, Yi EC, Schuster T, Zhang Y, Frederich RC, Friedman GS, Wang EQ, Tsamandouras N

Journal of clinical pharmacology1 May 2026Cited by 1 (Europe PMC)

PMID42053447 (opens in a new tab)PMCIDPMC13127352 (opens in a new tab)DOI10.1002/jcph.70158 (opens in a new tab)PepBankPUB-42053447
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy participants with overweight or obesity, co-administered semaglutide did not significantly change midazolam exposure (AUCinf and Cmax).

    In plain wordsIn healthy people with overweight or obesity, semaglutide did not significantly change blood levels of midazolam.

    Peptide
    Semaglutide
    Outcome
    No significant changeMidazolam exposure (AUCinf and Cmax) with semaglutide co-administration
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant changes were observed in midazolam exposure (AUCinf and Cmax) following co-administration with semaglutide.
    1 context sentence
    Summary · context
    Potential PK DDI between semaglutide and midazolam was also assessed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 1Results postedNCT05671653

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

Pfizern = 3219 Jan 2023 to 3 Nov 2023

Obesity

Trial pageClinicalTrials.govUpdated 14 Jan 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.